Oral Session 3-7A Multiple Myeloma: Daratumumab

[OS3-7A-2] Improvement in HRQoL with daratumumab, lenalidomide, and dexamethasone (D-Rd) vs Rd in NDMM: MAIA

Nizar J. Bahlis¹, Aurore Perrot², Thierry Facon³, Torben Plesner⁴, Saad Z Usmani⁵, Shaji Kumar⁶, Karthik Ramasamy⁷, Murielle Roussel⁸, Carla Araujo⁹, Arnaud Jaccard¹⁰, Michel Delforge¹¹, Jianping Wang¹², Rachel Kobos¹², Caroline McKay¹², Katharine S. Gries¹², Jeremiah Trudeau¹², Cyrille Hulin¹³, Katja Weisel¹⁴ (1.University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB, Canada, 2.Hematology Department, University Hospital, Vandoeuvre Les Nancy, France Metropolitan, 3.Service des Maladies du Sang, Hopital Claude Huriez, Lille, France Metropolitan, 4.Vejle Hospital and University of Southern Denmark, Vejle, Kingdom of Denmark, 5.Levine Cancer Institute/Atrium Health, Charlotte, NC, United States of America, 6.Department of Hematology, Mayo Clinic Rochester, Rochester, MN, United States of America, 7.Oxford University Hospital and NIHR BRC Blood Theme, Oxford, United Kingdom of Great Britain and Northern Ireland, 8.CHU Purpan/IUCT Oncopole, Toulouse, France Metropolitan, 9.Centre Hospitalier de la Cote Basque, Bayonne, France Metropolitan, 10.Centre Hospitalier Universitaire, Limoges, France Metropolitan, 11.Department of Hematology, University Hospital Leuven, Leuven, Kingdom of Belgium, 12.Janssen Global Services, Raritan, NJ, United States of America, 13.Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac, France Metropolitan, 14.Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Federal Republic of Germany)